Mitral Annular Disjunction in the Context of Mitral Valve Prolapse: Identifying the At-Risk Patient - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38703174/
Mitral annular disjunction (MAD), a separation between the left atrium/mitral valve annulus and the left ventricular myocardium, is frequently seen in patients with arrhythmic mitral valve prolapse. Although an association...
Mitral annular disjunction (MAD) is linked to ventricular arrhythmias but lacks clear risk stratification. Multimodality imaging aids diagnosis, while treatment includes surgery, medical therapy, ablation, and ICDs, requiring further prospective data.
Potential Diagnostic and Prognostic Values of Left Atrial Strain in Valvular Heart Disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39086705/
There has been increasing evidence supporting the importance of left atrial (LA) functional analysis and measurement in various physiologic and pathologic cardiovascular conditions due to its high diagnostic and prognostic...
Left atrial strain (LAS) via speckle-tracking echocardiography aids in early detection of subclinical dysfunction in valvular heart disease, guiding risk stratification, prognosis, and intervention timing to prevent irreversible myocardial damage.
Evaluation and Management of Chronic Heart Failure in Children and Adolescents With Congenital Heart Disease: A Scientific Statement From the American Heart Association - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38808502/
With continued medical and surgical advancements, most children and adolescents with congenital heart disease are expected to survive to adulthood. Chronic heart failure is increasingly being recognized as a major...
Chronic heart failure in children with congenital heart disease requires better understanding of its epidemiology, pathophysiology, and outcomes to develop evidence-based therapies and improve management strategies for this high-risk population.
Semaglutide significantly improved heart failure symptoms, physical limitations, body weight, exercise function, and reduced CRP levels in obesity-related HFpEF patients, with consistent benefits across subgroups and fewer serious adverse events.
Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38184132/
This meta-analysis showed that beta-blocker therapy has the potential to reduce all-cause mortality in patients with HFpEF based on observational studies. Nevertheless, it did not affect rehospitalization for heart failure...
Beta-blockers may reduce all-cause mortality in HFpEF patients but show no impact on heart failure rehospitalization. Large-scale randomized trials are needed to confirm their efficacy in this population.